Table 3. Adverse Events of Grade 3 or Higher or Serious Adverse Events Attributed to Eltrombopag^*.

Event	Patients (N = 92)
	no. (%)
Skin
Maculopapular rash†	2 (2)
Pruritus	1 (1)
Abdominal pain	2 (2)
Liver test abnormality	17 (18)
Increased alanine aminotransferase level	9 (10)
Increased aspartate aminotransferase level	3 (3)
Blood bilirubin increased	12 (13)

^*All the adverse events of grade 3 or higher that were attributed by the investigators to eltrombopag are shown. The data-cutoff date was May 25, 2016. Events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4. Patient 87 required a temporary dose reduction of cyclosporine and eltrombopag owing to conjugated bilirubinemia associated with pruritus. Eltrombopag was discontinued temporarily as mandated by the protocol in seven patients owing to a transient elevation in the liver-enzyme levels during the administration of antithymocyte globulin or during serum sickness that occurred during the first 2 weeks.

^†Severe adverse events were observed in Patient 54 (in cohort 2) and Patient 86 (in cohort 3), who had maculopapular rashes of grade 3 and 2, respectively, that were associated with fever and oral pain and that resulted in hospitalization, discontinuation of eltrombopag, and treatment with glucocorticoids.